Why Is Ozempic Cheaper in Other Countries? Prices and Patents
Ozempic and other GLP-1s cost less abroad because the US relies on high list prices with rebates, and semaglutide patents run years longer in the US. A US list price cut to $675 takes effect January 1, 2027, and importing the drug yourself is generally illegal.
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.
Ozempic costs less outside the US for two structural reasons: the way the US system prices drugs, and the length of US patent protection. In the US, manufacturers set a high list price, then pay rebates to insurers and issue patient coupons, so the list price is not what insurers pay [1]. But some people’s out-of-pocket costs are tied to the list price — Novo Nordisk names those with high-deductible health plans and coinsurance benefit designs as the group its list-price cut targets [3]. Abroad, semaglutide patents are also expiring years earlier: generics are already on the market in India, Canada approved its first generic in April 2026, and the US is protected from generic competition until 2032 [4][5][7]. Buying the cheaper foreign version yourself is, in most circumstances, illegal under FDA rules [8]. A lower US list price of $675 per month for Wegovy, Ozempic, and Rybelsus is scheduled to take effect January 1, 2027 [3].
How big is the price gap between the US and other countries?
A side-by-side comparison comes from a Peterson-KFF Health System Tracker brief published August 17, 2023, using list prices found through web searches as of August 15, 2023. These are 2023 list prices, not current prices and not what insurers actually paid then or pay now [1].
| Country | Ozempic 1 mg (1 month) | Rybelsus 7 mg (30 tablets) | Wegovy 2.4 mg (1 month) | Mounjaro 15 mg (4 pens) |
|---|---|---|---|---|
| United States | $936 | $936 | $1,349 | $1,023 |
| Japan | $169 | $69 | — | $319 |
| Canada | $147 | $158 | — | — |
| Switzerland | $144 | $147 | — | — |
| Germany | $103 | — | $328 | — |
| Netherlands | $103 | $203 | $296 | $444 |
| Sweden | $96 | $103 | — | — |
| United Kingdom | $93 | — | — | — |
| Australia | $87 | — | — | — |
| France | $83 | — | — | — |
A dash means the drug was not available or a price could not be found in that country at the time. Wegovy had launched in only a few European Union markets, and shortages in Australia and some other countries limited availability for people using semaglutide for diabetes [1].
Why does the US list price matter if insurers pay less?
List prices are not the same as net prices. Manufacturers pay rebates to insurers and issue patient coupons, and private insurers and employers in the US can negotiate lower prices or larger rebates [1]. For example, the Peterson-KFF brief noted that privately insured patients could get Wegovy coupons of $225 per 28-day supply for up to a year if their plan covered it, or $500 per 28-day supply if it did not [1].
But some patients’ out-of-pocket costs are tied directly to the list price. Novo Nordisk itself named people with high-deductible health plans and coinsurance benefit designs as the group its 2026 list-price cut is meant to help [3]. Public coverage adds another layer: Medicare is prohibited under current law from covering GLP-1s for obesity treatment [1][2]. Medicaid programs must cover GLP-1s for diabetes and, since March 2024 and December 2024, for cardiovascular disease (Wegovy) and obstructive sleep apnea (Zepbound) — but states may choose to exclude weight-loss drugs [2].
That state choice matters. Thirteen state Medicaid fee-for-service programs covered GLP-1s for obesity as of January 2026, down from 16 as of October 2025. California, New Hampshire, Pennsylvania, and South Carolina dropped coverage, while North Carolina reinstated it in December 2025 after a budget stalemate [2].
When does the lower $675 US list price take effect, and who does it help?
On February 24, 2026, Novo Nordisk announced that effective January 1, 2027, it will lower the US list price — the wholesale acquisition cost — to $675 per month across Wegovy injection 2.4 mg and tablets 25 mg, Ozempic 0.5 mg, 1 mg, and 2 mg, and Rybelsus 7 mg or 14 mg, applying to all doses. That is a reduction of roughly 50% for Wegovy and roughly 35% for Ozempic from the then-current list price [3].
Novo framed the move around the more than 100 million people living with obesity and more than 35 million with type 2 diabetes in the US [3]. One important limit: Novo states the change does not affect direct-to-patient, self-pay prices, such as what people pay through its own access channels [3].
Why is generic Ozempic available abroad but not in the US?
Semaglutide patents are expiring sooner in countries that did not grant patent extensions, including Canada, China, India, and Brazil [4]. In Canada, data exclusivity expired January 4, 2026, and the core semaglutide patent lapsed after missed maintenance fee payments [4]. In India, Novo’s semaglutide patent expired on Friday, March 20, 2026, and generics launched that same weekend [7].
In the US, semaglutide remains protected from generic competition until 2032 [7]. A BMO Capital Markets analyst said strong US intellectual property protections should prevent meaningful spillover from Canadian generics into the US market [6]. IQVIA estimates that about one-third of the world’s adults with obesity live in markets hit by this patent cliff [4].
What happened in Canada after the patent lapsed?
On April 28, 2026, Health Canada authorized the first generic semaglutide injection — made by Dr. Reddy’s Laboratories as a generic of Ozempic, and the first generic semaglutide approved in the G7. It is indicated for once-weekly treatment of adults with type 2 diabetes [5][6]. Health Canada completed the review within its 180-day target for generic submissions and is reviewing eight other generic semaglutide submissions, with decisions expected in the coming weeks and months [5][6].
In Canada, many generic medications are 45% to 90% cheaper than the brand-name versions [5][6]. Canadian policy drives list-price discounts of about 65% once three generic competitors are on the market [4]. Sandoz’s CEO, Richard Saynor, said the company expected the Canadian generic market to take shape in the third quarter of 2026, after Sandoz and Dr. Reddy’s were asked to provide more data [4]. Sandoz has described Canada as the world’s second-largest semaglutide market [4].
What happened in India after the patent expired?
At least five Indian drugmakers launched generic semaglutide the weekend after the patent expired, undercutting Novo’s original price by up to 80% [7]. Sun Pharma launched a weekly injection for as low as 750 rupees (about $8), or roughly 3,400 rupees per month [7]. Dr. Reddy’s launched its diabetes version at around 4,200 rupees per month and plans to expand to Canada, Turkey, and Brazil [7]. Natco Pharma’s vial runs 1,250 rupees per month, and Alkem’s prefilled injections start at 1,800 rupees per month [7]. Novo’s Indian retail price had been 8,800 to 10,000 rupees depending on dosage [7].
Novo had already cut the price of Wegovy in India by 37% from its launch price in late 2025, before the patent expired [7]. More than 50 brands are expected to launch generic semaglutide in India in the coming months, and Novo is selling second brands there — Wegovy as Poviztra through Emcure and Ozempic as Extensior through Abbott India [7]. Novo warned in February 2026 that its sales could decline 5% to 13% in 2026 [7].
Can I legally buy Ozempic from Canada or Mexico myself?
In most circumstances, it is illegal for individuals to import drugs into the US for personal use, and a drug approved abroad but unapproved in the US is illegal to import [8]. The FDA recommends obtaining medicines only from legal US sources, because it cannot ensure the safety or effectiveness of medicine bought over the internet from foreign sources, through storefront businesses, or on trips abroad [8].
The FDA’s personal-use discretion is not a right. FDA personnel may consider a more permissive decision only in narrow situations — for example, when a product treats a serious condition for which effective treatment may not be available domestically, is not promoted to US residents, does not present an unreasonable risk, is affirmed in writing as personal use, and is generally no more than a three-month supply, with either a US doctor’s name and address or evidence that treatment began abroad [8]. The FDA refuses personal imports when a product is on an import alert, appears intended for commercial distribution, appears to present a serious health risk, or appears to represent health fraud [8]. Foreign nationals visiting the US may bring or ship a 90-day supply [8].
What about counterfeit and quality risks from foreign or gray-market sellers?
IQVIA has warned that as more manufacturers enter the market, the dangers of counterfeiting and substandard quality are likely to be multiplied [4]. Novo has warned that unauthorized versions of its drugs carry safety risks and has pursued legal action against gray-market sellers, with mixed results [4].
Semaglutide is a peptide-based medicine that requires specialized manufacturing and a cold chain for storage, making quality control harder than for small-molecule drugs like painkillers, according to Knud Jensen, a chemistry professor at the University of Copenhagen [7]. There is also industry concern that Indian-made generics could leak into markets where semaglutide remains patent-protected [7]. Novo’s position is that all doses of its medicines are fully available in the US, so there is no reason to use compounded knock-off products [3].
What is the US government doing about the price gap?
In November 2025, the Trump administration announced a deal with Eli Lilly and Novo Nordisk to lower GLP-1 costs for Medicare, Medicaid, and people buying directly from the manufacturers through the TrumpRx website [2]. In December 2025, CMS introduced the BALANCE model, a five-year CMS Innovation Center model that negotiates lower GLP-1 prices and is voluntary for state Medicaid programs, Medicare Part D plans, and manufacturers, with standardized coverage criteria plus lifestyle supports [2].
Participation intentions were due January 8, 2026; the model is expected to begin in May 2026, with Part D implementation in January 2027 after a short-term demonstration letting Part D enrollees access obesity drugs beginning July 2026 [2]. KFF notes these announcements will not change costs for Medicaid enrollees, who already pay little or no copays for prescriptions, and that TrumpRx direct-purchase prices will likely still be prohibitive for households at Medicaid income levels [2]. The administration also declined to finalize a Biden-era proposal to allow Medicare and require Medicaid to cover obesity drugs [2].
Has the price gap actually closed yet?
Not as of the most recent published figures. The list-price gap documented in 2023 persists until the scheduled $675 US list price takes effect January 1, 2027 [1][3]. Meanwhile, the generic gap is widening in the other direction: Canada approved its first generic semaglutide in April 2026, India has many on the market, and the US is protected from generic competition until 2032 [5][7].
The two underlying drivers remain in place — a fragmented US purchasing system where list prices drive many patients’ costs, and longer US patent life [1][3][4][7]. The US also has by far the highest obesity rate among peer nations, 33.5% of adults versus a comparable-country average of 17.1%, which amplifies the spending impact of US prices [1].
Sources
- Peterson-KFF Health System Tracker. How do prices of drugs for weight loss in the U.S. compare to peer nations’ prices? August 17, 2023.
- KFF. Medicaid Coverage of and Spending on GLP-1s. January 16, 2026.
- Novo Nordisk. Novo Nordisk announces significant reduction in US list price for Wegovy, Ozempic, and Rybelsus (semaglutide medicines), building on continued efforts to expand access.
- Benefits and Pensions Monitor. Ozempic generics set to test Canada’s drug budgets. January 16, 2026.
- Health Canada. Canada becomes the first G7 country to approve a generic version of semaglutide. April 28, 2026.
- Reuters. Canada approves first generic version of Ozempic amid rising GLP-1 competition. April 28, 2026.
- CNBC. India is launching cheap weight-loss drugs — but Novo Nordisk is betting its brands will stay on top. March 23, 2026.
- US Food and Drug Administration. Personal Importation.
- GoodRx. Importing Prescription Medications From Canada: What You Need to Know.
- BBC News. Why Canadians can now get cheaper generic Ozempic — and Americans can’t. June 3, 2026.
- AMA Journal of Ethics. What Should Prescribers and Policy Makers Know About US Drug Importation? April 2024.
- The White House. Fact Sheet: President Donald J. Trump Announces Major Developments in Bringing Most-Favored-Nation Pricing to American Patients. November 6, 2025.
- The White House. Fact Sheet: President Donald J. Trump Launches TrumpRx.gov to Bring Lower Drug Prices to American Patients. February 5, 2026.
- RAND. International Prescription Drug Price Comparisons: Current Empirical Estimates and Comparisons with Previous Studies.
Frequently asked questions
Is Ozempic cheaper in Canada than the US, and by how much?
Yes. In the Peterson-KFF comparison of 2023 list prices, one month of Ozempic 1 mg listed at $936 in the US versus $147 in Canada. Those are 2023 list prices, not current prices or what insurers actually pay. Canada also approved its first generic semaglutide in April 2026, and many Canadian generics run 45% to 90% below brand prices.
Can I legally order semaglutide from a Canadian or Indian pharmacy?
In most circumstances, no. The FDA states it is illegal for individuals to import drugs for personal use, including drugs approved abroad but unapproved in the US, and recommends obtaining medicines only from legal US sources. The FDA's personal-use discretion applies only in narrow situations and is not a right.
Why is generic Ozempic available abroad but not in the US?
Semaglutide patents expire sooner in countries that did not grant extensions, including Canada, China, India, and Brazil. Canada's core patent lapsed after missed maintenance fees, and India's patent expired on March 20, 2026, triggering generic launches. In the US, semaglutide is protected from generic competition until 2032.
When will generic semaglutide be available in the United States?
No US availability date has been published. What is known is that semaglutide remains protected from generic competition in the US until 2032. A BMO analyst said strong US intellectual property protections should prevent meaningful spillover from Canadian generics.
What is the difference between list price and what insurers actually pay?
List price is the manufacturer's posted price, also called the wholesale acquisition cost. Insurers typically pay less after negotiated rebates, and manufacturers offer patient coupons — for example, a Wegovy coupon of $225 per 28-day supply cited in the Peterson-KFF brief. People with high-deductible plans or coinsurance often owe costs tied to the list price instead.
When does the lower $675 list price take effect, and who does it help?
January 1, 2027. Novo Nordisk announced on February 24, 2026 that Wegovy, Ozempic, and Rybelsus will list at $675 per month across all doses — roughly 50% off Wegovy and 35% off Ozempic. Novo says it targets patients whose out-of-pocket costs are tied to list price, and that direct-to-patient, self-pay prices are unaffected.
Does Medicare or Medicaid cover GLP-1s for weight loss?
Medicare is prohibited under current law from covering GLP-1s for obesity treatment. Medicaid coverage for weight loss is optional by state: 13 state fee-for-service programs covered GLP-1s for obesity as of January 2026, down from 16 in October 2025. Coverage is required for diabetes, cardiovascular (Wegovy), and sleep apnea (Zepbound) indications.
This article summarizes FDA labeling, published research and company information current as of September 14, 2026. It is not medical advice and does not replace a conversation with your own healthcare provider. How we research and verify.